April 18 (Reuters) – Merck Says Fourth Designation For
Keytruda Follows Breakthrough Status In Advanced Melanoma, Non
The post BRIEF-Merck receives breakthrough therapy designation from FDA for use of Keytruda in classical hodgkin lymphoma appeared first on NASDAQ.